Short interest for INmune Bio gives investors a sense of the degree to which investors are betting on the decline of INmune Bio's stock. Short interest data is updated every two weeks.

INmune Bio Stock (NASDAQ:INMB), Short Interest Report

INmune Bio

INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.

doctor-3822863_1280

News

Movers & Shakers

ELAB

INMB

Elevai Labs, Inc. (NASDAQ:ELAB) shares are trading higher Tuesday after the company announced it signed an exclusive, worldwide manufacturing and processing technology licensing agreement with INmune Bio, Inc. (NASDAQ:INMB).

Why Elevai Labs Stock Is Trading Higher

INmune Bio – Helping Your Own Cells Fight Cancer And Reverse Alzheimer’s Disease

Biotech

Interview

General

David Moss, CEO of INmune Bio (NASDAQ: INMB) was recently a guest on Benzinga’s All-Access.

INmune Bio – Helping Your Own Cells Fight Cancer And Reverse Alzheimer&#39;s Disease

Earnings

Penny Stocks

Eurozone

Commodities

Small Cap

Global

Intraday Update

Markets

APPH

APPS

BLBD

CSII

REVB

SCLX

U.S. stocks traded higher this morning, with the Dow Jones jumping around 250 points on Thursday.

The Dow traded up 0.75% to 34,204.99 while the NASDAQ rose 1.15% to 12,047.28. The S&amp;P 500 also rose, gaining, 0.75% to 4,148.69.

Dow Jumps 250 Points; US Jobless Claims Increase Last Week

INmune Bio Inc

INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.54) by 12.96 percent. This is a 69.44 percent decrease over losses of $(0.36) per share from the same period last year. The company reported quarterly sales of $14.000 thousand which missed the analyst consensus estimate of $30.000 thousand by 53.33 percent. This is a 63.16 percent decrease over sales of $38.000 thousand the same period last year.

Earnings Misses

INmune Bio Q1 2024 GAAP EPS $(0.61) Misses $(0.54) Estimate, Sales $14.000K Miss $30.000K Estimate

INmune Bio Provides Update On Two Patients From Phase 1b Alzheimer's Disease Trial Receiving XPro Under Compassionate Use; Says 'Reports from the primary care physicians indicate that XPro has been well-tolerated throughout the treatment period, with stable cognitive function observed in the patients.'

INmune Bio Completes First Cohort And Initiates Second Cohort Of Phase 1/2 Study Of INKmune Natural Killer Cell Therapy In Patients With Metastatic Castration-Resistant Prostate Cancer

INmune Bio Says Remains On Track In Line With Prior Guidance To Complete Its Phase 2 Clinical Trial Involving The Use Of XPro For The Treatment Of Alzheimer's Disease In Patients With Biomarkers Of Neuroinflammation

Offerings

INmune Bio Announces $9.7M Registered Direct Offering Of 986,000 Shares And Warrants At $9.84/Share And Accompanying Warrant

INmune Bio Announces 24-Month Stability Validation Of XPro For Phase III Readiness And Commercial Supply Chain Modeling & Development Of Novel Immunogenicity Assay

<a href="https://www.globenewswire.com/Tracker?data=gvmWdStBEy_CgwJgL3vp4BFwUVPWfjNYbo2LmCMnVLo3jq3Sq67wpsbOWvACZSCfVhcz8-9M8ZgH72dpbzO2nDBHNM-KQqfifbkmAMZkbss=">INmune Bio, Inc.&nbsp;</a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) (the "Company"), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today&nbsp;announced today that it has entered into definitive agreements for the sale and purchase of 571,592 shares of its common stock with above market warrant exercise price &nbsp;that include an acceleration clause upon positive top-line data in the Company's Phase 2 Alzhzimer's Disease program (as further described &nbsp;below).&nbsp; The warrants give the investor the right to purchase 571,592 additional shares of its common stock in a registered direct offering. The offering was priced at the market based on the Friday, April 19th&nbsp;Nasdaq consolidated closing bid price of $8.32 per share. The exercise price of the warrants is $9.152, which represents a 10% premium to the price at which the common shares were offered. The warrants terminate on the earlier of (1) the two (2) year anniversary of the initial exercise date of the warrant or (2) thirty (30) trading days following the reporting of top line data (EMACC) in the Phase 2 Alzheimer's program of XPro1595, (the "Termination Date"). The gross proceeds of this offering are approximately $4.8 million before deducting placement agent fees and expenses. The closing of the offering is expected to occur on or about April 24, 2024, subject to the satisfaction of customary closing conditions. Members of management and the Company's board of directors and certain key employees participated in the offering and will pay a combined offering price for the common stock and warrants of $8.445 per share and warrant, and &nbsp;in the case of officers and directors that participated in the offering, if the warrant termination date is on a blackout date then the officers and directors will have an additional 60 days from the termination of the blackout date to exercise the warrant. &nbsp;
The Company intends to use the net proceeds for completing the ongoing Phase 2 trial (AD02) in patients with Early Alzheimer's Disease (AD) using XPro&#x2122; and the metastatic castration-resistant prostate cancer (mCRPC) Phase 1 trial using the INKmune technology.&nbsp;&nbsp;
LifeSci Capital is acting as sole placement agent for this offering.&nbsp;&nbsp;&nbsp;

INmune Bio Inc. Raises ~$4.8M In Gross Proceeds Through Registered Direct Offering With Officers, Employees And Directors Purchasing ~20% Of The Offering

Novel Immunotherapy Approach Targets Soluble Tumor Necrosis Factor to Overcome Resistance and Enhance Therapeutic Outcome in High-Risk Breast Cancer
Boca Raton, Florida, April 08, 2024 (GLOBE NEWSWIRE) -- &nbsp;<a href="https://www.globenewswire.com/Tracker?data=GCytWNTcYVaSYNhadgCBTNreZuO9eKl_xHmpkRZtYqs82e-3IMHpteVkDi_kxvMML5XoFqAEa92C5-mYrJW2x2ZOICsoNSw4Uztj9oIi_xQ=">INmune Bio, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) (the "Company"), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, is presenting data on the use of INB03, a dominant-negative tumor necrosis factor (TNF) inhibitor of soluble TNF (sTNF) in the treatment of high-risk MUC4 expressing HER2+ and triple negative breast cancer (TNBC).&nbsp; INB03 is shown to decrease T cell and macrophage immune checkpoint proteins (PD1, TIGIT, LAG3, CD47 and SIRPa) in a model immunotherapy resistant HER2+ breast cancer and decrease the metastatic potential of TNBC by downregulating cell surface markers of tumor invasion (MUC4, SNAIL and Vimectin).&nbsp; The two posters will be presented at the annual American Association of Cancer Research in San Diego on April 8, 2024.
The poster, titled, "INB03: a new immune checkpoint inhibitor that reprograms macrophage polarization, boosts ADCP and reverts T-cell exhaustion markers" outlines the use of human macrophages and T cells in a MUC4+HER2+ syngeneic breast cancer model to demonstrate that the combination of INB03 with an anti-HER2 antibody 4D5 has five distinct effects on the tumor biology, which results in decreased tumor growth (p&lt;0.001).&nbsp; These include: &nbsp;
i.&nbsp; &nbsp; &nbsp; &nbsp;a decrease in MUC4 expression
ii.&nbsp; &nbsp; &nbsp; a 3-fold increase in T cell infiltration
iii.&nbsp; &nbsp; &nbsp;polarization of tumor macrophages from M1 (immunosuppressive) to M2 (anti-tumor macrophages)
iv.&nbsp; &nbsp; &nbsp;a doubling of antibody dependent cellular phagocytosis (ADCP) and
v.&nbsp; &nbsp; &nbsp; a decrease in the expression of innate immune checkpoint proteins (CD47 and SIRP-a) and T cell checkpoint proteins (TIGIT, CTLA-4, PD1 and LAG-3)
In the study, the increase in T cell infiltrate did not occur unless both anti-HER2 and INB03 immunotherapy were used in combination.&nbsp; Decreases in T cell and macrophage immune checkpoint proteins were caused by INB03. All changes in immune parameters are p&lt;0.05 unless otherwise stated.&nbsp; The authors concluded that INB03 enhances the M1-like phenotype and reprograms already-polarized pro-tumoral M2-like macrophages to antitumoral ones.&nbsp; Further, it promotes ADCP against HER2+ tumor cells by downregulating the ADCP inhibitory axis CD47-SIRPα-B7H4 in vitro.&nbsp; Finally, the addition of INB03 to 4D5 treatment promotes T cell infiltration to the TME and downregulates immune checkpoint molecules and T cell exhaustion markers in vitro and in vivo.&nbsp; The authors speculate that these effects could avoid tumor immune evasion to anti-HER2 targeted therapies by reinvigorating the immune infiltrate. The poster can be found on the Company's web site.
A second poster, titled, "MUC4 is a biomarker of metastasis in TNBC and its downregulation by blocking soluble TNF prevents metastasis in combination with immunotherapy," studies the importance of MUC4 expression in TNBC survival.&nbsp; Approximately half of women with TNBC express MUC4.&nbsp; Overall survival of women with MUC4 expressing TNBC is dramatically worse (p&lt;0.005) with almost a 5-fold increased risk of death (p&lt;0.018). MUC4 expression in the tumor negatively correlated with fewer Tumor Infiltrating Lymphocytes (TILs, p&lt;0.003), PD-L1 (p&lt;0.001) and Ki67 (p&lt;0.036) expression.&nbsp; &nbsp;In human TNBC cell lines, INB03 decreased the expression mesenchymal markers of invasive capacity, MUC4, SNAIL and Vimectin, and decreased activity in an invasion assay (p&lt;0.01).&nbsp;
In a murine LMM3 model, treatment with the combination of INB03 and anti-PD1 checkpoint antibodies dramatically decreased lung metastasis with no animals receiving combination therapy having &gt;3 lesions compared to 40% of control animals (p&lt;0.05).&nbsp; The authors concluded: i) MUC4 expression is an independent biomarker of poor overall survival and is associated with an increased risk of metastasis in TNBC patients; ii) MUC4 is inversely correlated with TILs, and is associated with tumors with low proliferative rate (Ki67&lt;30%) and negative PD-L1: it would be useful to identify tumors resistant to chemotherapy and immunotherapy; iii) TNF blockade decreases MUC4 expression, mesenchymal markers and reduces invasive capacity in TNBC cell lines; &nbsp;iv) soluble TNF blockade in combination with anti PD-1 antibody prevents the establishment of lung metastases in a preclinical model of TNBC.&nbsp; They further propose soluble TNF as a new target for the treatment of TNBC, and MUC4 as a predictive marker to guide a combined treatment with selective sTNF neutralization with immunotherapy. The poster can be found on the Company's web site.
Dr. Schillaci, senior author of the study, proposes INB03 is a new class of immunotherapy called a pan immune checkpoint modulator in MUC4 expressing breast cancer.&nbsp; INB03 isn't a selective immune checkpoint inhibitor targeting a specific immune checkpoint protein; rather, it downregulates all immune checkpoint proteins present on both T cells and macrophages. "Soluble TNF, secreted by cancer cells, shields tumors from immune attacks by altering the tumor microenvironment, rendering the patient's immune response ineffective and fostering resistance to immunotherapy. Through extensive research, we have unraveled the mechanisms underlying the tumor protecting role of soluble TNF which causes tumors to proliferate. Translating these findings into targeted strategies for high-risk breast cancer, we can devise a precision medicine approach to counteract soluble TNF's effects, reversing therapy resistance, preventing&nbsp; metastasis,&nbsp;and empowering the immune system to combat tumors effectively," said Dr. Schillaci
"Dr. Schillaci has shown that MUC4 expression in high-risk breast cancer subtypes is a predictor of resistance to therapy due to an unfavorable immunobiology of the TME and increased metastatic potential that is driven by soluble TNF," said RJ Tesi M.D., CEO of INmune Bio. "Neutralization of soluble TNF changes a resistant tumor biology into one that is more favorable.&nbsp; &nbsp;
All of the individuals involved in this project share the belief that prospectively determining MUC4 expression in high-risk breast cancer subtypes will guide therapy decisions and significantly impact patient outcomes."
The posters will be presented at AACR on April 8:
PO.IM01.02 - Immune Checkpoints and Inhibitory Molecules 1 9 am
INB03: a new immune checkpoint inhibitor that reprograms macrophage polarization, boosts ADCP and reverts T-cell exhaustion markers by Sofia Bruni, Maria Florencia Mercogliano and Roxana Schillaci
PO.TB04.02. Biomarkers and Expression Differences in Metastatic Progression 1.30 pm
MUC4 is a biomarker of metastasis in TNBC and its downregulation by blocking soluble TNF prevents metastasis in combination with immunotherapy by Mauro, Florencia; Bruni, S; Dupont, A; Inurrigarro, G; Figurelli, S; Barchuk, S, Lopez Della Vecchia, D; Cordo Russo, R;Gil Deza, E; Mercogliano, M; Schillaci, Roxana
As this science is presented at AACR, the Company plans to expand its business development efforts in search of the right partner to advance the clinical development of a combination therapy with INB03.&nbsp; "We believe these findings reflect novelty and inventive step, and further support the expansion of our evolving patent portfolio covering INB03 for oncology indications, in particular, use of INB03 to target soluble TNF in combination with antibodies and other anti-cancer therapies," said Joshua Schoonover, General Counsel of INmune Bio. "Through our collaborations with academic and other research institutions, such as Dr. Schillaci's lab at CONICET, INmune Bio has learned much about INB03, including its effects on tumor biology, which enables us to explore a number of cancer treatment indications and commercial applications of the drug, and further supports partnership efforts with the goal of improving the efficacy of certain anti-cancer therapies by combining them with INB03." Interested parties should inquire with the Company for more information about available partnering opportunities.
About INB03
INB03 is a DN-TNF inhibitor that neutralizes soluble TNF (sTNF) without affecting trans membrane TNF (tmTNF) or TNF receptors.&nbsp; Compared to currently available non-selective TNF inhibitors, INB03 preserves the immune response to cancer by decreasing immunosuppressive cells in the TME including TAM and MDSC while promoting recruitment of anti-tumor immune cells including cytolytic CD8+ lymphocytes, NK cells and anti-tumor macrophages.&nbsp; INB03 has completed an open label dose-escalation Phase I trial in patients with advanced cancer.&nbsp; In that trial, INB03 was found to be safe and well tolerated - no dose limiting toxicity was found.&nbsp; INB03 decreased blood biomarkers of inflammation in patients with advanced cancer.&nbsp;

INmune Bio Inc. Presents Data On INB03's Role As An Immune Check Point Modulator In The Treatment Of High-Risk Breast Cancer At AACR 2024

INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) reported its Q4 earnings results on Thursday, March 28, 2024 at 04:01 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
INmune Bio missed estimated earnings by -7.000000000000001%, reporting an EPS of $-0.47 versus an estimate of $-0.44.
Revenue was down $69 thousand from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company missed on EPS by $0.07 which was followed by a 4.0% drop in the share price the next day.

To track all earnings releases for INmune Bio <a href="https://www.benzinga.com/quote/INMB/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

INmune Bio: Q4 Earnings Insights

INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.44) by 6.82 percent. This is a 46.87 percent decrease over losses of $(0.32) per share from the same period last year. The company reported quarterly sales of $28.00 thousand which missed the analyst consensus estimate of $40.00 thousand by 30.00 percent. This is a 71.13 percent decrease over sales of $97.00 thousand the same period last year.

INmune Bio Q4 EPS $(0.47) Misses $(0.44) Estimate, Sales $28.00K Miss $40.00K Estimate

<h3>Companies Reporting Before The Bell</h3>
&bull; Universal Stainless (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAP#NASDAQ">USAP</a>) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million.
&bull; Shimmick (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHIM#NASDAQ">SHIM</a>) is estimated to report quarterly loss at $0.20 per share on revenue of $158.50 million.
&bull; MSC Industrial Direct Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSM#NYSE">MSM</a>) is estimated to report quarterly earnings at $1.16 per share on revenue of $946.55 million.
&bull; Walgreens Boots Alliance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) is likely to report quarterly earnings at $0.75 per share on revenue of $33.03 billion.
&bull; Data Storage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTST#NASDAQ">DTST</a>) is projected to report earnings for its fourth quarter.
&bull; Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) is likely to report quarterly loss at $1.68 per share on revenue of $1.71 million.
&bull; Atour Lifestyle Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAT#NASDAQ">ATAT</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $168.26 million.
&bull; CNFinance Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNF#NYSE">CNF</a>) is likely to report quarterly earnings at $0.01 per share on revenue of $65.41 million.
&bull; BRP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOOO#NASDAQ">DOOO</a>) is estimated to report quarterly earnings at $1.92 per share on revenue of $2.05 billion.
&bull; OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) is estimated to report quarterly earnings at $0.26 per share on revenue of $26.47 million.
&bull; Azul (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZUL#NYSE">AZUL</a>) is likely to report quarterly earnings at $0.14 per share on revenue of $985.30 million.
&bull; Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) is projected to report earnings for its fourth quarter.
&bull; Iterum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRM#NASDAQ">ITRM</a>) is expected to report earnings for its fourth quarter.
&bull; DarioHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRIO#NASDAQ">DRIO</a>) is projected to report quarterly loss at $0.54 per share on revenue of $3.57 million.
&bull; Cheche Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCG#NASDAQ">CCG</a>) is expected to report earnings for its fourth quarter.
&bull; Telesat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSAT#NASDAQ">TSAT</a>) is projected to report earnings for its fourth quarter.
&bull; Jiayin Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFIN#NASDAQ">JFIN</a>) is projected to report earnings for its fourth quarter.
&bull; IM Cannabis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCC#NASDAQ">IMCC</a>) is estimated to report quarterly loss at $0.17 per share on revenue of $10.45 million.
&bull; Smart Share Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EM#NASDAQ">EM</a>) is expected to report earnings for its fourth quarter.
&bull; 36KR Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRKR#NASDAQ">KRKR</a>) is projected to report earnings for its fourth quarter.
&bull; 22nd Century Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) is estimated to report quarterly loss at $0.55 per share on revenue of $17.10 million.
&bull; China Automotive Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAAS#NASDAQ">CAAS</a>) is estimated to report earnings for its fourth quarter.
&bull; REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) is expected to report quarterly earnings at $0.68 per share on revenue of $190.26 million.
&bull; D-Wave Quantum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) is projected to report quarterly loss at $0.10 per share on revenue of $4.73 million.
&bull; Hut 8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) is expected to report quarterly loss at $0.25 per share on revenue of $23.66 million.
&bull; American Oncology Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AONC#NASDAQ">AONC</a>) is estimated to report earnings for its fourth quarter.
&bull; Gold Royalty (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GROY#AMEX">GROY</a>) is estimated to report quarterly loss at $0.01 per share on revenue of $1.90 million.
&bull; Better Home &amp; Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BETR#NASDAQ">BETR</a>) is projected to report earnings for its fourth quarter.
&bull; BOS Better Online Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOSC#NASDAQ">BOSC</a>) is projected to report earnings for its fourth quarter.
<h3>Companies Reporting After The Bell</h3>
&bull; INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) is estimated to report quarterly loss at $0.44 per share on revenue of $40 thousand.
&bull; Dolphin Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLPN#NASDAQ">DLPN</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $11.10 million.
&bull; Ascent Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACNT#NASDAQ">ACNT</a>) is expected to report quarterly loss at $0.08 per share on revenue of $63.50 million.
&bull; Kodiak Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOD#NASDAQ">KOD</a>) is expected to report earnings for its fourth quarter.
&bull; Pineapple Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $20.40 million.
&bull; Oxford Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXM#NYSE">OXM</a>) is projected to report quarterly earnings at $1.95 per share on revenue of $408.18 million.
&bull; Naas Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAAS#NASDAQ">NAAS</a>) is estimated to report earnings for its fourth quarter.
&bull; Danimer Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNMR#NYSE">DNMR</a>) is projected to report quarterly loss at $0.38 per share on revenue of $11.33 million.
&bull; Dare Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DARE#NASDAQ">DARE</a>) is expected to report quarterly loss at $0.10 per share on revenue of $1.79 million.
&bull; Intellinetics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INLX#AMEX">INLX</a>) is estimated to report quarterly earnings at $0.04 per share on revenue of $4.10 million.
&bull; Shapeways Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPW#NASDAQ">SHPW</a>) is expected to report quarterly loss at $0.95 per share on revenue of $9.25 million.
&bull; NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) is expected to report earnings for its fourth quarter.
&bull; CVD Equipment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVV#NASDAQ">CVV</a>) is projected to report earnings for its fourth quarter.
&bull; Nuvve Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVVE#NASDAQ">NVVE</a>) is expected to report quarterly loss at $5.60 per share on revenue of $3.00 million.
&bull; NexGel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXGL#NASDAQ">NXGL</a>) is projected to report quarterly loss at $0.11 per share on revenue of $1.38 million.
&bull; ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) is expected to report earnings for its fourth quarter.
&bull; Zevra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVRA#NASDAQ">ZVRA</a>) is estimated to report quarterly loss at $0.27 per share on revenue of $11.74 million.
&bull; American Res (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREC#NASDAQ">AREC</a>) is projected to report quarterly loss at $0.04 per share on revenue of $2.20 million.
&bull; Vicinity Motor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEV#NASDAQ">VEV</a>) is estimated to report quarterly loss at $0.06 per share on revenue of $12.62 million.
&bull; Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) is likely to report quarterly loss at $3.77 per share on revenue of $250 thousand.
&bull; Surf Air Mobility (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NYSE">SRFM</a>) is likely to report quarterly loss at $0.28 per share on revenue of $25.69 million.
&bull; Emeren Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $44.98 million.
&bull; P3 Health Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) is expected to report quarterly loss at $0.11 per share on revenue of $302.97 million.
&bull; Energous (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WATT#NASDAQ">WATT</a>) is estimated to report quarterly loss at $0.85 per share on revenue of $200 thousand.
&bull; Dyadic International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>) is likely to report quarterly loss at $0.06 per share on revenue of $800 thousand.
&bull; Semtech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) is projected to report quarterly loss at $0.03 per share on revenue of $196.46 million.
&bull; Torrid Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) is likely to report quarterly loss at $0.08 per share on revenue of $274.83 million.
&bull; Pulse Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) is likely to report earnings for its fourth quarter.
&bull; Arcadia Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKDA#NASDAQ">RKDA</a>) is projected to report quarterly loss at $2.58 per share on revenue of $1.75 million.
&bull; Achieve Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHV#NASDAQ">ACHV</a>) is projected to report earnings for its fourth quarter.
&bull; Sharecare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHCR#NASDAQ">SHCR</a>) is expected to report quarterly loss at $0.06 per share on revenue of $114.99 million.
&bull; Expion360 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) is projected to report quarterly loss at $0.28 per share on revenue of $980 thousand.
&bull; Cepton (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPTN#NASDAQ">CPTN</a>) is expected to report quarterly loss at $0.74 per share on revenue of $2.46 million.
&bull; Vuzix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VUZI#NASDAQ">VUZI</a>) is estimated to report quarterly loss at $0.15 per share on revenue of $2.14 million.
&bull; Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) is estimated to report quarterly loss at $0.45 per share on revenue of $2.54 million.
&bull; Forian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORA#NASDAQ">FORA</a>) is estimated to report quarterly loss at $0.03 per share on revenue of $5.56 million.
&bull; Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) is estimated to report quarterly loss at $0.62 per share on revenue of $3.45 million.
&bull; Wrap Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRAP#NASDAQ">WRAP</a>) is likely to report earnings for its fourth quarter.
&bull; Planet Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) is projected to report quarterly loss at $0.06 per share on revenue of $58.19 million.
&bull; Leafly Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFLY#NASDAQ">LFLY</a>) is likely to report quarterly loss at $1.45 per share on revenue of $9.49 million.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

ACHV

ACNT

AFMD

AONC

AREC

ATAT

AXDX

AZUL

BETR

BOSC

CAAS

CPTN

CURV

DARE

DLPN

DNMR

DOOO

DRIO

DTST

DYAI

FORA

GROY

HSDT

IMCC

IMNN

INLX

ITRM

JFIN

KRKR

LFLY

NAAS

NDRA

NRXP

NVVE

NXGL

OPRX

PEGY

PIII

PLSE

QBTS

RKDA

SHCR

SHIM

SHPW

SMTC

SRFM

TSAT

USAP

VUZI

WATT

WRAP

XPON

XXII

ZVRA

Earnings Scheduled For March 28, 2024

INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) is set to give its latest quarterly earnings report on Thursday, 2024-03-28. Here's what investors need to know before the announcement.
Analysts estimate that INmune Bio will report an earnings per share (EPS) of $-0.44. 
INmune Bio bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company missed EPS by $0.07, which was followed by a 3.82% drop in the share price the next day.
Here's a look at INmune Bio's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.41</td>
<td>-0.40</td>
<td>-0.02</td>
<td>-0.48</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.48</td>
<td>-0.36</td>
<td>-0.36</td>
<td>-0.32</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.0%</td>
<td>-10.0%</td>
<td>4.0%</td>
<td>-7.000000000000001%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1711562474_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of INmune Bio were trading at $11.88 as of March 26. Over the last 52-week period, shares are up 99.42%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/INMB/earnings">To track all earnings releases for INmune Bio visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Preview Of INmune Bio's Earnings

Patients with Alzheimer's Disease show improvement in brainwaves following 4 weeks of XPro&#x2122; therapy.
Boca Raton, Florida, March 05, 2024 (GLOBE NEWSWIRE) --&nbsp; <a href="https://www.globenewswire.com/Tracker?data=owEG-ybVR9W3s84V7ENafSvHFhYHAIo_2e31OB53lR_mvYb5ShRw1Y2bIq2zE3wMvW8tIa0NDECTc5jUkrsyrmSambaKznkac9a3ZkpHRZEMN1QJA8uAQTcpnHt6K9AO_zz76sw289DDUSNQEMN5NNDiJuZyWVT-T_hcR9uOdcyAJrBAmVrZi0DlxgSeyDxCaqoparS3qhVNponVNNeX4zlBkErN1lny07OcdLdt7ZkyoJpdM4nr6SygWNqAKzhULzelYAnqzoXnxvPwG25zhbAogxn8SM_PnOObQKyOA4a_Y5wK31vgrZ1vZJ-8Bif-8i8aKEe1IjdzcfgLsMhhaT9GzOCuGF9mgXHX3POrKepVl5k4WDxmiehg7_aYfIgfrxlRd2mvZqPaQxCumodkRip5siyoC1F1KOdUVutwOMTB9Z-mzj-f4hpOehcTWcuQajo4af16MMW2hLWXRouG-A==">INmune Bio, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>)&nbsp;(the "Company"), a clinical-stage immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer's disease (AD) reports significant improvements in electroencephalography (EEG), a biomarker of brain function, in patients with moderate to severe Alzheimer's Disease treated with XPro&#x2122; for four weeks.
Patients who received weekly XPro&#x2122; treatment for four weeks had a statistically significant increase in Alpha wave frequency and power (p&lt;0.05). Reduced Alpha power is linked with cognitive decline and the progression of Alzheimer's Disease. Alpha waves represent synchronized brain network activity that&nbsp;are essential for internal functions like mental arithmetic, short-term and working memory, and visual-spatial mental imagery exercises. &nbsp;In individuals with AD, Alpha wave power is diminished due to the breakdown of brain networks associated with degeneration.
"Functional benefits are the true benchmark of a drugs biological efficacy, and these promising findings are part of a larger narrative that's still unfolding," stated CJ Barnum, PhD, VP of Neuroscience at INmune Bio. &nbsp;"We are committed to extensive research, drawing from our Phase 2 placebo-controlled trial to substantiate these findings."
The seven patient pilot study in patients with moderate to severe AD sought to evaluate the utility of EEG as a functional biomarker of target engagement in evaluating the effects of XPro&#x2122; (XPro1595;&nbsp;pegipanermin), a next generation dominant-negative inhibitor of soluble TNF, in AD patients. These positive results support and add to the findings of the Phase 1 study in patients with AD that showed XPro&#x2122; treatment reduced biomarkers of inflammation and improved biomarkers of neurodegeneration, synaptic function and improved brain microstructure and promoted remyelination. The extent to which these biomarker changes impact cognition in patients with Early Alzheimer's Disease is currently being assessed in our ongoing randomized, placebo-controlled Phase&nbsp;2&nbsp;trial.
EEG, long considered a gold standard in objectively measuring brain activity, provides valuable insight into neural connectivity. Neurological research has consistently highlighted a progressive decline in alpha band power and frequency in individuals with MCI and Alzheimer's disease. EEG's capability to assess brain function makes these findings particularly noteworthy for INmune Bio's novel treatment strategy. The use of EEG as a biomarker for brain function and its potential as a regular measure in clinical trials was facilitated by Cumulus Neuroscience's innovative, FDA approved, portable EEG device.
"It is unprecedented to continuously monitor brain function at this scale. Our goal is to bring reliable, clinic-level brain function measurement into the comfort and familiarity of a patient's home," remarked Brian Murphy, Ph.D., Chief Scientific Officer of Cumulus Neuroscience. "The work highlights the untapped potential in utilizing task-synchronized EEG throughout the drug-development process in patients with Alzheimer's disease, which could revolutionize how clinical trials are conducted and treatments are evaluated." &nbsp;
Echoing this sentiment, Dr. Barnum emphasized, "Our work with Cumulus Neuroscience is forging new paths in Alzheimer's research, by empowering us with the ability to observe&nbsp;real-time effects of XPro&#x2122; on brain function directly within patients' everyday lives."
About EEG and Alpha Band Power in AD
EEG is the gold standard for measuring brain activity; informing on how well neurons are connected within the brain. Quantitative EEG is reported by the frequency and magnitude of the electrical signal. The frequency of the EEG is categorized by bands that correspond to distinct brain activities and states whereas the magnitude measures how active the neurons are within each band.
The alpha band power, defined around the 8 to 12 Hz frequency band, increases during internal tasks such as mental calculation, short-term and working memory or visual-spatial mental imagery exercises (Vaitl et al., 2005; Klimesch, Sauseng and Hanslmayr, 2007; Palva and Palva, 2007; Lutz, Dunne, and Davidson, 2012). It broadly reflects coordinated network activity in the brain and is expected to be reduced by the "disconnection" of networks seen in neurodegeneration.
In the context of natural aging, alpha power magnitude and frequency has been observed to reduce over the lifespan (Klimesch, 1999; Scally et al., 2018) and positively correlate with individual level of cognitive performance among a group of people of a similar age (Clark et al., 2004). In diseased populations, there is broad evidence connecting a fall in alpha power and frequency to cognitive decline and disease progression (Babiloni et al., 2020; Lejko et al., 2020). Reductions in alpha power and frequency are also associated with traumatic brain&nbsp;injury and have been observed to increase during recovery (Ianof and Anghinah, 2017; Conley et al., 2018).&nbsp; Specifically, global reduction in alpha power and frequencies are observed in MCI (Mild Cognitive Impairment) patients compared to healthy older adults, and progressive MCI is characterized by lower resting alpha power and frequencies compared to stable MCI (Lejko et al., 2020). Longitudinal studies in AD patients have also reported lower magnitude and frequency of alpha rhythms after yearly follow-up (Babiloni et al., 2020, 2024).

INmune Bio Reports Significant EEG Improvement In Alzheimer's Patients Treated With XPro

INmune Bio Announces FDA Removal Of Clinical Hold For Alzheimer's Disease Program

- SEC Filing
&nbsp;
On January 16, 2023, Elevai Labs, Inc., a Delaware corporation (the "Company"), entered into a License Agreement (the "License Agreement") with INmune Bio, Inc., a Nevada corporation ("INmune"). Under the License Agreement, INmune granted the Company certain worldwide exclusive and non-exclusive license rights to develop, manufacture, and commercialize INmunes's EMx technology, ("EMx") a proprietary equipment, processes and consumables useful for isolation and current Good Manufacturing Practice ("cGMP") manufacture of human umbilical cord derived mesenchymal stromal cells ("hUMSCs",) for a period of ten years from the effective date of the License Agreement (collectively, the "Field").
Pursuant to the License Agreement, the Company will make an upfront payment to INmune as a technology transfer fee with scheduled payments six months after the effective date of the License Agreement and upon completion of the transfer of EMx. In addition, Elevai will pay INmune (i) a final technology transfer fee two years after the effective date of the License Agreement, and (ii) a capped nominal royalty on the sale of licensed topical cosmetic products that are manufactured using EMx. After the Company's first successful manufacturing that utilizes the Field, the Company has agreed to supply INmune with hUMSCs at a price pegged at a fixed percentage above the actual cost for the Company to produce them.
&nbsp;
Unless earlier terminated, the License Agreement will remain in effect on a licensed product-by-licensed product and worldwide basis until the expiration of the License Agreement. Either party may terminate the License Agreement for insolvency of the counter-party, or material breach by the other party within the time period specified in the agreement.
&nbsp;

Contracts

On Jan 16, Elevai Labs Inc Entered Into A License Agreement With INmune Bio, Inc.; INmune Granted The Co Certain Worldwide Exclusive And Non-Exclusive License Rights To Develop, Manufacture, And Commercialize INmunes's EMx Technology

Elevai Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAB#NASDAQ">ELAB</a>) shares are trading higher Tuesday after the company announced it signed an exclusive, worldwide manufacturing and processing technology <a href="https://www.benzinga.com/news/earnings/24/01/36642878/dow-dips-200-points-goldman-sachs-earnings-top-views">licensing agreement with INmune Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>).</a>
The Details:
The<a href="https://www.benzinga.com/pressreleases/24/01/g36640266/elevai-labs-inc-acquires-worldwide-license-agreement-for-proprietary-stem-cell-manufacturing-techn"> licensing agreement</a> grants Elevai a license to use INmune Bio&#8217;s proprietary &#8220;EMx&#8221; technology that enables Elevai to manufacture current Good Manufacturing Practice (cGMP) grade, human umbilical cord-derived mesenchymal stromal cells (hucMSCs) at a lower cost to Elevai than purchasing hucMSCs outright. Manufactured hucMSCs can be incorporated into certain licensed topical cosmetic products sold in the medical aesthetics skincare market.
Under the agreement, Elevai will make an initial deposit for the license in two installments over six months, and a final tech transfer fee within two years of executing the agreement. As further consideration under the agreement, Elevai will be required to pay a nominal royalty on the sale of licensed topical cosmetic products that are manufactured using the EMx technology.
&#8220;Partnering with INmune Bio, Inc. aligns perfectly with our mission to pioneer innovative stem cell exosome products. Their understanding of efficient human stem cell isolation and large-scale manufacturing provides us with a remarkable opportunity to expand our manufacturing capabilities, expand our product portfolio, and make a significant impact in the market,&#8221; stated Jordan R. Plews, Ph.D., CEO of Elevai Labs.
Related News: <a href="https://www.benzinga.com/news/24/01/36614767/whats-going-on-with-lucid-group-stock">What&#8217;s Going On With Lucid Group Stock?</a>
ELAB Price Action: According to<a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw"> Benzinga Pro</a>, Elevai Labs shares are up 7.6% at $1.84 at the time of publication.
Image: Mohamed Hassan from Pixabay

ELEVAI Labs Signs Exclusive Worldwide Manufacturing Agreement And License Agreement With INmune Bio Granting ELEVAI A License To Use INmune's EMx Technology

INKmune&nbsp;is a biologic therapy given as out-patient therapy&nbsp;without the need for pre-medication or cytokine support.

Health Care

INmune Bio Dosed The First Patient In The Phase 1/2 Trial Of INKmune In Men With Metastatic Castration-resistant Prostate Cancer

Enrollment in the Company's Phase II study using XProTM to treat patients with Alzheimer's Disease with neuroinflammation is accelerating in sites outside the US and the Company is maintaining its timeline to successfully conclude the trial.
In the US, the previously identified clinical hold issues have been successfully addressed however the Phase II study remains on clinical hold pending additional information on long-term stability which the Company will provide before the end of 2023.

INmune Bio On Track To Complete Enrollment Of Phase II Clinical Trial In Patients With Early Alzheimer's Disease And Biomarkers Of Inflammation In 2024; FDA Said U.S. Phase II Trial Remains On Full Clinical Hold Pending Additional Information Request

<a href="https://www.globenewswire.com/Tracker?data=rgqPHplK3lC3LaQwqTK07vKIZwsSE8WGHx610HinF38ScqiHz_mdFCB0pInwTpH0QKwbMsrLaGOth6cqBwrUK48sibtZ-pV4efJN3Vh2UpeHwDLlw8G1ANLXen0yEUCyeQnmM3ktg4KFeqzwZJmXeZ0MXCoRhDu9ajQAJ8H62QOpAFGSqbKl1m7XtSdwzJOrTJfspG6ijLilsfaqeE1ijZLr2pQoQxsICU7Hg1RYuBNDxy7jh88td6OZmsZfV3hEkdJbpJWXxCmJwQpZOms7WwF0BE7gVXA_wYA3Q4TYOxK4yAJm5OFDzaxH1MfNZwi4G-1wW_YpXiLE4HAnrTE5RU-VYRimpr6ms_cXyvJ9obqUYHCs7jhuKWS02cJ2kVe8WPOjbQ8qX855JVKPLoeHFRjkv4fkydLLPf65rp5zkcCzhDRi7WfaNdG31iksrlAz342t6nOCXSCzplQqG5dfP1N4aFvps5wWrsjjDl_0wJdfNSC5_0qaweka9QSoDRyEs8yootuctvf6z85ky_16BRQcVVH4gG2TQsYCDQpGhmjwPXKIL2OP7RDxzORWZfx6kDLml6uCCUCyr1ik--AIyl4R5m4P_ELVOZfHZ9kKNOF8HqopR5EYfeTfGLemtuQaZoHyhJ-s-peFj2Wee11kuipvZF72--hO6RAGLs1QKI2cMNU_FZScUNSFyTzWcv-x97umaskGHJsQ6-CmgdvdmPfaLNIyGfsf-DKDqZH4zMA=" target="_blank">INmune Bio, Inc.&nbsp;</a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) (the &quot;Company&quot;), a clinical-stage immunology company focused on developing treatments that harness the patient&#39;s innate immune system to fight disease, is&nbsp;presenting data on the use of INB03, a dominant-negative TNF inhibitor of soluble TNF (sTNF) in the treatment of high-risk MUC4 expressing HER2. Roxana Schillaci, Ph.D., of Instituto de Biolog&iacute;a y Medicina Experimental in Buenos Aries, Argentina, will present her work at the 46th&nbsp;annual San Antonio Breast Cancer Symposium, which runs from December 5 to 9.

INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium

Robert W. Baird analyst Joel Beatty maintained a Buy rating on Inmune Bio (INMB – Research Report) on April 9 and set a price target of $16.00. Joe...

Inmune Bio's INB03 Shows Promise as Pan-Immune Checkpoint Inhibitor: A Buy Rating from Analyst Joel Beatty

INmune Bio: An Opportunity In The Freefall (Rating Upgrade)

INmune Bio rises 2%, on $4.5M direct offering

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Inmune Bio (INMB – Research Report), with a price target...

Inmune Bio Earns Buy Rating on Positive XPro Developments and Strong Financials

Analyst Kaveri Pohlman of BTIG maintained a Buy rating on Inmune Bio (INMB – Research Report), with a price target of $21.00. Kaveri Pohlman has gi...

INKmune Program's Promise in mCRPC Treatment: A High-Risk, High-Reward Investment with a Favorable Safety Profile

INmune Bio provides update on Alzheimer's candidate XPro

Maxim Group analyst Jason McCarthy has maintained their bullish stance on INMB stock, giving a Buy rating yesterday. Jason McCarthy has given his B...

Inmune Bio's Promising INKmune Therapy and Strong Financials Merit a Buy Rating

INmune Bio files for $250M mixed shelf offering

Notable earnings after Thursday's close

INmune Bio reports Q1 GAAP EPS of -$0.61

AAOI

ACHR

ACIC

ACTG

ADMA

AETUF

AKAM

INDI

INSG

IOVA

IVVD

JUSHF

KODK

LCTX

LEGH

LOMA

LPTH

LSTA

LTBR

LTRN

MERC

MGNX

MTNB

MTUS

MVIS

MVST

NGVC

NKTR

NTRA

NVTS

ONCT

ONCY

ONTO

ORGO

OUST

PACB

PANL

PDFS

PGNY

PHUN

PLBY

PLNH

PODD

QRHC

RGTI

RICK

RVNC

RXRX

SGMO

Press Releases

INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28

INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update

INmune Bio Inc. Presents Data on INB03's Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024

INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with  Officers, Employees and Directors Purchasing Approximately 20% of the Offering

INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay

INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer

INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer's Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years

INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9

INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update

Acumen Pharmaceuticals, Inc. - Common Stock

Acumen Pharmaceuticals

Adverum Biotechnologies, Inc. - Common Stock

Adverum Biotechnologies

-

-

-

-

-

-

-

-

-

-

-

-

-

-

INmune Bio Stock (NASDAQ:INMB), Short Interest Report

People Also Watch